Laura Kristin Newby

Laura Kristin Newby's AcademicInfluence.com Rankings

Laura Kristin Newby

Medical

#2976

World Rank

#3424

Historical Rank

Cardiology

#299

World Rank

#305

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Laura Kristin Newby Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Laura Kristin Newby's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker (2008) (2315)
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). (2002) (1878)
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. (2011) (1730)
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker (2008) (1569)
2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. (2013) (1456)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (1234)
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. (2004) (1024)
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. (2011) (895)
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. (2007) (873)
ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemaker (2008) (866)
Acute Coronary Care in the Elderly, Part I. Non–ST-Segment–Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology (2007) (859)
ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. (2008) (836)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. (2007) (720)
Association between hospital process performance and outcomes among patients with acute coronary syndromes. (2006) (708)
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. (2005) (681)
Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/Ameri (2005) (643)
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. (2005) (637)
ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. (2008) (563)
Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. (2010) (557)
Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction (2008) (502)
Sex differences in mortality following acute coronary syndromes. (2009) (483)
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. (1996) (438)
Acute Coronary Care in the Elderly, Part II: ST-Segment–Elevation Myocardial Infarction A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology (2007) (421)
Early versus delayed, provisional eptifibatide in acute coronary syndromes. (2009) (406)
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016) (396)
Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease (2006) (393)
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. (2007) (376)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. (2007) (376)
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. (2012) (367)
Twelve-Year Follow-Up of American Women's Awareness of Cardiovascular Disease Risk and Barriers to Heart Health (2010) (340)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. (2007) (333)
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. (2006) (321)
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. (2002) (294)
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. (1998) (293)
Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction (2001) (287)
2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. (2013) (287)
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. (2019) (275)
Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative (2006) (272)
Strategies for Improving Survival After In-Hospital Cardiac Arrest in the United States: 2013 Consensus Recommendations A Consensus Statement From the American Heart Association (2013) (265)
2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2012) (256)
National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. (2007) (255)
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial (2000) (252)
Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy (2001) (233)
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. (2004) (232)
A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. (2014) (221)
Role of Noninvasive Testing in the Clinical Evaluation of Women With Suspected Ischemic Heart Disease: A Consensus Statement From the American Heart Association (2014) (212)
Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non–ST-Elevation Myocardial Infarction (2009) (208)
Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRU (2009) (203)
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation (2008) (183)
Prognostic significance of elevated troponin I after percutaneous coronary intervention. (2002) (183)
Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. (2013) (179)
Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CR (2006) (175)
ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. (2005) (169)
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical issues for biochemical markers of acute coronary syndromes. (2007) (168)
Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis (2011) (166)
Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review. (2015) (160)
Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. (2008) (148)
Results of a reevaluation of cardiovascular outcomes in the RECORD trial. (2013) (147)
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. (2006) (146)
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. (2000) (141)
Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. (2002) (141)
Cardiovascular outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II) (2002) (140)
Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. (1996) (138)
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. (2001) (136)
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes (2004) (135)
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes (1998) (134)
Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. (2004) (132)
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. (2009) (129)
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial (2014) (120)
Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). (2006) (119)
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. (2000) (118)
Impact of Time of Presentation on the Care and Outcomes of Acute Myocardial Infarction (2008) (111)
Bedside Multimarker Testing for Risk Stratification in Chest Pain Units: The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study (2001) (108)
National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. (2008) (108)
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients (2003) (107)
Advancing the Study of Stroke in Women: Summary and Recommendations for Future Research From an NINDS-Sponsored Multidisciplinary Working Group (2006) (107)
Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. (2008) (107)
Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. (2011) (102)
Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. (2009) (100)
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. (2003) (94)
Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes (2002) (92)
Medication Errors in Acute Cardiovascular and Stroke Patients: A Scientific Statement From the American Heart Association (2010) (92)
Age Moderates the Short-Term Effects of Transdermal 17β-Estradiol on Endothelium-Dependent Vascular Function in Postmenopausal Women (2007) (91)
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. (2013) (87)
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro (2005) (84)
Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019) (84)
Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. (2006) (83)
Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. (2019) (82)
Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes. (2003) (81)
ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (writing Committee to Update the 199 (2007) (80)
Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. (2003) (79)
Ten-Year Differences in Women's Awareness Related to Coronary Heart Disease: Results of the 2019 American Heart Association National Survey: A Special Report From the American Heart Association. (2020) (78)
Prospects for personalized cardiovascular medicine: the impact of genomics. (2005) (77)
Poverty, process of care, and outcome in acute coronary syndromes. (2003) (77)
Early statin initiation and outcomes in patients with acute coronary syndromes. (2002) (76)
Renal function, concomitant medication use and outcomes following acute coronary syndromes. (2005) (75)
Prognostic performance of a high-sensitivity cardiac troponin I assay in patients with non-ST-elevation acute coronary syndrome. (2014) (74)
Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit. (2000) (74)
Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. (2006) (72)
A comparison of acute coronary syndrome care at academic and nonacademic hospitals. (2007) (69)
Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative. (2007) (69)
Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. (2000) (69)
Implementation strategies for improving survival after out-of-hospital cardiac arrest in the United States: consensus recommendations from the 2009 American Heart Association Cardiac Arrest Survival Summit. (2011) (68)
Hypercholesterolemia Paradox in Relation to Mortality in Acute Coronary Syndrome (2009) (67)
Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). (2013) (67)
Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes (2012) (66)
Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: is therapeutic hypothermia one possibility? (2012) (65)
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. (2002) (64)
Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. (1993) (64)
Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. (2002) (63)
Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. (2007) (62)
A randomized controlled trial of paroxetine for noncardiac chest pain. (2006) (62)
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients (2014) (59)
Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. (2009) (59)
Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease (2003) (58)
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. (2006) (57)
Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. (2005) (57)
Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non–ST-Segment–Elevation Acute Coronary Syndromes: Results From the SYNERGY Trial (2007) (57)
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. (2004) (57)
Cardiac markers: point of care testing. (1999) (56)
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. (2004) (55)
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. (2003) (55)
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). (2006) (52)
Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. (2015) (50)
Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease (2006) (48)
Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. (1997) (48)
Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. (2019) (47)
Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. (2005) (46)
Impact of Comorbidities on Ischemic Stroke Outcomes in Women (2008) (46)
Hospital length of stay in patients with non-ST-segment elevation myocardial infarction. (2012) (46)
Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? (1996) (45)
Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the EARLY ACS Trial (2012) (44)
Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome: An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial (2011) (44)
Role of target vessel size and body surface area on outcomes after percutaneous coronary interventions in women. (2002) (44)
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. (2005) (43)
International variation in the use of evidence-based medicines for acute coronary syndromes. (2003) (43)
Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. (2008) (42)
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial (1999) (42)
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. (2013) (41)
Seeking the optimal aspirin dose in acute coronary syndromes. (2002) (41)
Who refuses enrollment in cardiac clinical trials? (2007) (41)
Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. (2010) (40)
The Clinician as Investigator: Participating in Clinical Trials in the Practice Setting (2004) (40)
COCATS 4 Task Force 13: Training in Critical Care Cardiology. (2015) (39)
Biomarkers in cardiovascular clinical trials: past, present, future. (2012) (39)
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. (2003) (39)
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry (2019) (39)
Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. (2011) (38)
Medication Errors in Acute Cardiac Care: An American Heart Association Scientific Statement From the Council on Clinical Cardiology Subcommittee on Acute Cardiac Care, Council on Cardiopulmonary and Critical Care, Council on Cardiovascular Nursing, and Council on Stroke (2002) (38)
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. (2002) (38)
International variation in invasive care of the elderly with acute coronary syndromes. (2006) (37)
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials (2011) (37)
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). (2003) (36)
ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Update the 199 (2007) (35)
Preoperative evaluation for major noncardiac surgery: focusing on heart failure. (2004) (35)
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. (2008) (35)
Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. (2008) (34)
Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort (2020) (34)
Aspirin Use Post-Acute Coronary Syndromes: Intolerance, Bleeding and Discontinuation (2003) (34)
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years (2015) (33)
Inflammation as a Treatment Target after Acute Myocardial Infarction. (2019) (33)
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. (2006) (32)
The chest-pain unit--ready for prime time? (1998) (32)
Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites. (2008) (32)
Diagnosis and Management of Patients With Myocardial Injury After Noncardiac Surgery: A Scientific Statement From the American Heart Association. (2021) (32)
Get with the guidelines steering committee and investigators. Impact of time of presentation on the care and outcome of acute myocardial infarction (2008) (32)
The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. (2012) (30)
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature. (2012) (30)
Biochemical markers in suspected acute myocardial infarction: the need for early assessment. (1995) (30)
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. (2012) (30)
Failure to Launch (2017) (30)
Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. (2010) (29)
Do stable non-ST-segment elevation acute coronary syndromes require admission to coronary care units? (2016) (29)
How much do we gain by reducing time to reperfusion therapy? (1996) (28)
Diabetes-related knowledge, atherosclerotic risk factor control, and outcomes in acute coronary syndromes. (2005) (28)
ACCF/AHA 2007 clinical competence statement on vascular imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training: developed in collaborat (2007) (27)
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials (2018) (27)
Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. (2003) (27)
The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes. (2006) (25)
Effectiveness of practices for improving the diagnostic accuracy of Non ST Elevation Myocardial Infarction in the Emergency Department: A Laboratory Medicine Best Practices™ systematic review. (2015) (25)
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. (2004) (25)
Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. (2010) (24)
Nighttime blood pressure dipping in postmenopausal women with coronary heart disease. (2012) (24)
1077-71 The association between care and outcomes in patients with acute coronary syndrome: National results from CRUSADE (2004) (23)
Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). (2007) (23)
Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke? (2015) (23)
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. (2013) (23)
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. (2007) (23)
Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction (2017) (23)
Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to Chagas disease. (2013) (23)
Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. (2006) (23)
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. (1998) (23)
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. (2013) (22)
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. (2013) (22)
The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. (2004) (22)
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study) (2019) (22)
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. (2013) (22)
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. (2007) (22)
Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. (2020) (22)
Cardiac markers in the assessment of acute coronary syndromes. (1997) (21)
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials (2016) (21)
Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns (2005) (20)
Use of Guidelines-Recommended Management and Outcomes Among Women and Men With Low-Level Troponin Elevation: Insights From CRUSADE (2009) (20)
Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. (2013) (20)
Prognostic Implications of Low Level Cardiac Troponin Elevation Using High‐Sensitivity Cardiac Troponin T (2015) (19)
Medication Discontinuation in the IMPROVE-IT Trial (2019) (19)
Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes. (2005) (19)
Prognostic Value of Troponins in Patients with Non‐ST‐segment Elevation Acute Coronary Syndromes and Chronic Kidney Disease (2008) (19)
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). (2005) (18)
Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. (2012) (18)
Focusing on Inflammation in the Treatment of Atherosclerosis (2004) (18)
Closing the Gap: Treating Hypertension in Women (2008) (18)
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). (2007) (17)
Statin use and stroke outcomes in the Heart and Estrogen–Progestin Replacement Study (HERS) (2004) (17)
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod (2015) (16)
Markers of cardiac ischemia, injury, and inflammation. (2004) (16)
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. (2014) (15)
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. (2013) (15)
Association 2013 Consensus Recommendations: A Consensus Statement From the American Heart Strategies for Improving Survival After In-Hospital Cardiac Arrest in the United States: (2013) (15)
Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings (2020) (14)
The relationship between meteorological conditions and index acute coronary events in a global clinical trial. (2013) (14)
Myocardial infarction rule-out in the emergency department: are high-sensitivity troponins the answer?: comment on "One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T". (2012) (14)
Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. (2007) (14)
Lessons Learned From a Clinical Trial (2004) (13)
Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes (MERLIN TIMI-36) study (2008) (13)
Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. (2010) (12)
Guidelines-based treatment of anaemic STEMI patients: practice patterns and effects on in-hospital mortality: a retrospective analysis from the NCDR (2013) (12)
Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes (2016) (12)
National academy of clinical biochemistry laboratory medicine practice guidelines: Point of care testing, oversight, and administration of cardiac biomarkers for acute coronary syndromes (2007) (12)
Association between Angiographic Complications and Clinical Outcomes among Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: An EARLY ACS Angiographic Substudy (2012) (12)
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. (2013) (12)
Does ranolazine have a place in the treatment of acute coronary syndromes? (2007) (11)
An Automated Strategy for Bedside aPTT Determination and Unfractionated Heparin Infusion Adjustment in Acute Coronary Syndromes: Insights from PARAGON A (2002) (11)
Present and evolving role of eptifibatide in the treatment of acute coronary syndromes (2007) (10)
Prognostic Biomarkers in Individuals with Prevalent Coronary Heart Disease (2009) (10)
The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease (2021) (10)
Diagnostic time course, treatment, and in-hospital outcomes for patients with ST-segment elevation myocardial infarction presenting with nondiagnostic initial electrocardiogram: a report from the American Heart Association Mission: Lifeline program. (2013) (10)
Oral platelet glycoprotein IIb/IIIa inhibition (2000) (10)
Postmenopausal hormone use in women with acute coronary syndromes. (2004) (10)
Association of genetic variants in the HDL receptor , SRB 1 , with abnormal lipids in women with coronary artery disease (2003) (10)
Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). (2014) (10)
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS (2013) (10)
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. (2017) (9)
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. (2020) (9)
Relationship Between Peak Troponin Values and Long‐Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes (2017) (9)
Left ventricular dysfunction screening in hypertensive patients with N-terminal pro-B-type natriuretic peptide and electrocardiogram. (2012) (8)
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME‐V study) (2020) (8)
Comparison of 30-day outcome, resource use, and coronary artery disease severity in patients with suspected coronary artery disease with and without diabetes mellitus assigned to chest pain units. (2003) (8)
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. (2011) (8)
The Clinician as Investigator: Participating in Clinical Trials in the Practice Setting Appendix 1: Fundamentals of Study Design (2004) (8)
Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm (2021) (8)
Troponins in pericarditis: implications for diagnosis and management of chest pains patients. (2000) (8)
Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study (2022) (8)
Relationship of Outcomes to Treatment with Lamifiban in Patients Undergoing PTCA: Analysis of PARAGON A (1997) (7)
Markers of cardiac ischemia and inflammation. (2005) (7)
Myocardial Ischemia on Exercise Stress Echocardiography Testing Is Not Associated with Changes in Troponin T Concentrations. (2017) (7)
Extended-release ranolazine: critical evaluation of its use in stable angina (2011) (7)
The emerging role of myoglobin for risk stratification. (2001) (7)
Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions. (2016) (6)
Anger control and cardiovascular outcomes. (2013) (6)
Assessment and Treatment of Patients with Type 2 Myocardial Infarction and Acute Non-Ischemic Myocardial Injury (2019) (6)
Patterns and implications of B-type natriuretic peptide measurement in patients with non-ST-segment elevation acute coronary syndromes. (2007) (6)
Ferric carboxymaltose improved symptoms and quality of life in patients with chronic heart failure and iron deficiency (2010) (6)
Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis (2021) (6)
Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial Infarction. (2018) (6)
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. (2013) (6)
Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician (2010) (6)
Review: Omega-3 fatty acid supplements provide no protective benefit in cardiovascular disease (2012) (6)
Association of race with complications and prognosis following acute coronary syndromes. (2004) (5)
Identifying patient risk: The basis for rational discharge planning after acute myocardial infarction (2004) (5)
TransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium. (2013) (5)
Practice patterns and clinical outcomes among non‐ST‐segment elevation acute coronary syndrome (NSTE‐ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE‐ACS (EARLY‐ACS) trial (2014) (5)
Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. (1999) (5)
Acute coronary syndromes in patients with diabetes mellitus: Diagnosis, prognosis, and current management strategies (2003) (5)
Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. (2016) (5)
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. (2007) (5)
Cardiac marker testing: where should we focus? (2000) (5)
Abstract 9150: Re-Elevation of Troponin Following Percutaneous Coronary Intervention Significantly Predicts 1-Year Mortality in Patients with High-risk Non-ST-Segment Elevation Acute Coronary Syndromes (2011) (5)
884-3 Clinical implications of discordant creatine kinase-MB and troponin results in patients with acute coronary syndromes (2004) (5)
Acute coronary syndromes in the elderly (2011) (5)
Biomarkers: Troponin testing—risk stratification to stratified medicine (2015) (4)
Understanding Population Cardiovascular Health: Harnessing the Power of Electronic Health Records. (2015) (4)
1154-90 Suboptimal treatment of patients with non-ST elevation acute coronary syndromes presenting with positive baseline troponin values (2004) (4)
Navigating the scylla and charybdis of chest pain management in the emergency department. Is a computer the answer? (2002) (4)
Risk factor management after acute coronary syndromes (2009) (4)
Abstract 11021: Lack of Implementation of ESC/ACC Definition of Myocardial Infarction in Contemporary Randomized Clinical Trials (2010) (4)
P ender Disparities in the Diagnosis and Treatment of on – ST-Segment Elevation Acute Coronary Syndromes arge-Scale Observations (2016) (4)
Applying the evidence in coronary disease secondary prevention: a call to action. (2014) (4)
Intravenous Beta-Blockers for Cardioprotection in STEMI: The Saga Continues. (2016) (4)
Provocative biomarker stress test: stress-delta N-terminal pro-B type natriuretic peptide (2018) (4)
Sex Differences in Medical Care after Acute Myocardial Infarction: What Can Be Done to Address the Problem? (2009) (4)
Reconciling Systems for Acute Myocardial Infarction Definition and Coding Classification. (2017) (3)
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). (2009) (3)
Platelets and Atherothrombosis: An Essential Role for Inflammation in Vascular Disease — A Review (2011) (3)
SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? (2022) (3)
UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL (2010) (3)
High-Sensitivity Troponin in Noncardiac Surgery: Pandora’s Box or Opportunity for Precision Perioperative Care? (2018) (3)
The significance of elevated troponin T in patients with nondialysis‐dependent renal insufficiency: A validation with coronary angiography (2005) (3)
Combining IIb/IIIa Inhibition and Heparin for Acute Coronary Syndromes: Evidence of a Gradient for Bleeding Hazard from the PARAGON Randomized Factorially Designed Trial (1997) (3)
Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate (2016) (3)
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. (2013) (3)
Implications of High-Sensitivity Troponin Testing: Learning From Those Who Came Before Us. (2018) (3)
Serum Markers for Diagnosis and Risk Stratification in Acute Coronary Syndromes (1999) (3)
Oral Glycoprotein IIb/IIIa Antagonists: New Insights from the SYMPHONY Trial (2004) (3)
Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction∗∗A complete list of the TAMI Study Group appears in J Am Coll Cardiol 1992;19:482–489. (2000) (3)
Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation in acute coronary syndromes (1997) (3)
Evaluation of Acute Chest Pain in Women (2004) (3)
Optimal dosing of a glycoprotein IIb/IIIa antagonist with simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B (2001) (2)
AHA Scientific Statement Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain A Scientific Statement From the American Heart Association (2010) (2)
PEER REVIEWED PUBLICATIONS 1. Ali YS, Maron DJ. Screening for coronary disease in diabetes: when and how. Clin Diabetes 2006; 24:169- 173. (2007) (2)
Erratum: Management of cardiovascular disease patients with confirmed or suspected covid-19 in limited resource settings (Global Heart (2020) 15:1 (44) DOI: 10.5334/gh.823) (2020) (2)
Rivaroxaban in Acute Coronary Syndromes: We Have a Compass and an Atlas, But Where Are We Headed? (2019) (2)
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. (2013) (2)
869-4 Sex disparities in the treatment of non-ST-segment elevation acute coronary syndromes (2004) (2)
Back to the future: improving the use of guidelines-recommended coronary disease secondary prevention at the dawn of the precision medicine era. (2015) (2)
Treatment pathways and quality improvement for patients with acute myocardial infarction at a tertiary care center. (2012) (2)
Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes (2005) (2)
In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality (2022) (2)
Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: insights from SYMPHONY, a large international trial (2001) (2)
The Role of Troponin in Risk Stratification (2004) (2)
Moderate obesity is associated with better intermediate-term survival in acute coronary syndromes: Results from the SYMPHONY and 2nd SYMPHONY clinical trials (2003) (1)
Platelet Inhibitors: What Are the Data in Women? (2008) (1)
Post-traumatic pancreatitis. (1990) (1)
Evidence-Based Guidelines for Cardiovascula r Disease Prevention in Women: 2007 Updat e (2007) (1)
SEX DIFFERENCES IN HIGH-RISK ACUTE CORONARY SYNDROMES: INSIGHTS FROM EARLY-ACS (2010) (1)
Abstract 12776: Non-ST-segment Elevation Acute Coronary Syndromes Patients without Angiographically Detected Obstructive Coronary Artery Disease are Low-risk but Not No-risk: A Meta-analysis of 8 Trials of 37,101 Patients (2010) (1)
Review: In patients with heart failure, β-blockers reduce mortality but do not differ from each other (2013) (1)
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. (2013) (1)
Failure to launch (2013) (1)
Practice Guidelines : Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure (2007) (1)
Cardiac markers for decision making in acute ischemic syndromes 1 1 The authors have provided an ext (2000) (1)
High-Sensitivity Troponin in Acute Heart Failure Triage. (2019) (1)
Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry. (2016) (1)
Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy (2016) (1)
Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA) (2020) (1)
To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question (2017) (1)
Opportunities for Enhancing the Use of Evidence-Based Medicines for Acute Coronary Syndromes: Insights From the Symphony Studies (2002) (1)
Association Between Angiographic Complications During Percutaneous Coronary Intervention and Clinical Outcomes Among Patients with Acute Coronary Syndrome: An EARLY ACS Angiographic Substudy (2011) (1)
Randomisation in the SYMPHONY trial (2000) (1)
Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure National Academy of Clinical Biochemistry Laboratory Medicine Practice (2008) (1)
Risk Factors and Outcomes Associated With Hypertensive Disorders of Pregnancy in Maternal Congenital Heart Disease (2022) (1)
TRENDS IN USE OF ANTI-THROMBOTIC AGENTS IN PATIENTS WITH NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (NSTEMI) MANAGED WITH AN INVASIVE STRATEGY: ANALYSIS FROM THE NCDR® (2012) (1)
In coronary artery disease, PCI increases all-cause and cause-specific mortality compared with CABG (2021) (1)
Response by McCord et al to Letter Regarding Article, "Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation "High-Sensitivity" Cardiac Troponin Assays to Diagnose Myocardial Infarction". (2019) (1)
Abstract 9904: Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials (2013) (1)
Implementation of High-Sensitivity Cardiac Troponin Assays in the United States. (2022) (1)
Abstract 3527: Decline in GP 2b3a Inhibitor Overdosing with Site-Specific Feedback in CRUSADE (2007) (1)
Sex, Region, and Outcomes After Revascularization. (2017) (1)
Abstract 1800: Unfractionated Heparin Dosing and Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndromes (2007) (1)
Elevated plasma natriuretic peptide levels were associated with cardiovascular events. (2004) (1)
SHORTER HOSPITAL STAYS AND OUTCOMES AFTER NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (2014) (1)
New biomarkers in the risk stratification of patients with suspected acute myocardial infarction (2002) (1)
Simpli fi ed Predictive Instrument to Rule Out Acute Coronary Syndromes in a High-Risk Population (2015) (1)
Correction: Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study (2022) (1)
The inter-relationship between creatinine clearance, cardiac troponin T and outcomes in patients with acute coronary syndromes (2002) (1)
Comparison of a Blood Self-Collection System with Routine Phlebotomy for SARS-CoV-2 Antibody Testing (2022) (1)
ASSOCIATION OF HUB AND SPOKE PRACTICE PATTERNS WITH CORONARY INTERVENTION AND OUTCOMES IN NON ST ELEVATION ACUTE CORONARY SYNDROMES (NSTE ACS): INSIGHTS FROM THE EARLY GLYCOPROTEIN IIB/IIIA INHIBITION IN NSTE ACS (EARLY-ACS) TRIAL (2011) (1)
A new biomarker of acute coronary ischaemia: from bench to bedside? (2021) (1)
Simplifying risk stratification in non-ST-segment elevation acute coronary syndromes (2005) (0)
Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials (2001) (0)
Global Outcomes ( KDIGO ) Controversies Chronic kidney disease and valvular heart disease : conclusions from a Kidney Disease : Improving Conference (2019) (0)
In response to "is non-dipping status related to coronary heart disease in postmenopausal women?". (2013) (0)
Adverse Pregnancy Outcomes Are Associated With Increased Risk for Mortality (2006) (0)
non-ST-segment elevation acute coronary syndromes Troponin: an important prognostic marker and risk-stratification tool in (2009) (0)
Response to Letter Regarding Article, “Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease” (2006) (0)
Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the CRUSADE initiative (2011) (0)
TEMPORAL TRENDS OVER 15 YEARS IN CLINICAL TRIALS OF NON-ST ELEVATION ACUTE CORONARY SYNDROMES: MORE AGGRESSIVE TREATMENT YIELDS SIMILAR MORTALITY DESPITE HIGHER-RISK PROFILES (2010) (0)
TIMING OF ELECTROCARDIOGRAPHIC DIAGNOSIS IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS WITH AN INITIAL NON-DIAGNOSTIC ELECTROCARDIOGRAM: AN OBSERVATIONAL ANALYSIS FROM THE NCDR® (2012) (0)
Non-ST-Segment Elevation Acute Coronary Syndrome Mortality: An Analysis of B-Type Natriuretic Peptide and Cardiac Troponin (2005) (0)
Cardiac Troponin After Revascularization Procedures (2006) (0)
111 Delayed Stress-Delta High Sensitivity Troponin Does Not Elevate With Myocardial Ischemia (2015) (0)
Heart Disease: A Consensus Statement From the American Heart Association Role of Noninvasive Testing in the Clinical Evaluation of Women With Suspected Ischemic (2014) (0)
Response to the Letter to the Editor titled "Atrial fibrillation in patients with acute coronary syndromes". (2014) (0)
Review: CABG reduces long-term mortality and morbidity more than PCI in multivessel coronary disease (2014) (0)
Book Reviews (2003) (0)
Responding to the letter to the editor by Saver. (2013) (0)
EVALUATION OF MEDICATION PERSISTENCE IN THE IMPROVE-IT TRIAL (2016) (0)
In STEMI with multivessel CAD, complete revascularization reduced CV death or MI more than culprit lesion–only PCI (2019) (0)
In HF with LVEF ≤ 42.5%, sacubitril–valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization (2020) (0)
Statement From the American Heart Association Medication Errors in Acute Cardiovascular and Stroke Patients : A Scientific (2012) (0)
109 Delayed Stress Delta N-Terminal Pro-B Type Natriuretic Peptide Is Significantly Higher With Myocardial Ischemia (2015) (0)
The Role of Enzymatic Markers in the New Millennium: Point-of-Care Testing and Beyond (1998) (0)
Long term use of eicosapentaenoic acid reduced major coronary events in hypercholesterolaemia (2007) (0)
1042-82 White blood cell count predicts higher risk of intermediate-term outcomes in patients stabilized after acute coronary syndromes: Observations from the SYMPHONY and 2ndSYMPHONY trials (2004) (0)
FREQUENCY, CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS, AND OUTCOMES OF HIGH-RISK NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES PATIENTS WITH LEFT CIRCUMFLEX CULPRIT LESIONS (2012) (0)
Simplified Predictive Instrument to Rule Out Acute Coronary Syndromes in a High‐Risk Population (2015) (0)
Clinical Investigations Safety of Selective Serotonin Reuptake Inhibitor Use Prior to Coronary Artery Bypass Grafting (2010) (0)
In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y (2022) (0)
METABOLITE FACTOR LEVELS VARY WITH AGE BUT RELATIONSHIPS OF FACTORS WITH OUTCOMES ARE CONSTANT ACROSS AGE (2013) (0)
Abstract 9147: Undiagnosed Diabetes Mellitus, Pre-Diabetes, and Outcomes in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes (2011) (0)
GP IIb–IIIa Inhibitors Administered Upstream: Evidence for Improved Outcomes With Conventional and Newer Antithrombotic Agents? (2008) (0)
Abstract 16456: Cardiac Troponin Levels Do Not Change in Response to Exercise Stress Testing (2014) (0)
Defibrillator therapy improved quality of life in CHF; amiodarone did not (2009) (0)
In patients at high CV risk receiving simvastatin, the Myopathy Risk Score predicted statin-related myopathy (2020) (0)
Abstract 16958: Are We There Yet? Dissipating Sex Differences in Acute Coronary Syndromes. A Population Level Examination (2016) (0)
Abstract 14185: Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes (2011) (0)
PLASMA AND TISSUE METABOLOMIC PROFILING IN A PORCINE ISCHEMIA-REPERFUSION MODEL REVEALS NOVEL EARLY MARKERS OF MYOCARDIAL INJURY (2010) (0)
In-hospital cardiac arrest: Complex clinical challenges in need of unique solutions. (2017) (0)
Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil (2012) (0)
Review: Counseling and educational methods that target multiple CV risk factors do not reduce mortality in adults without CHD (2011) (0)
Outpatient Medication Titration in Acute Heart Failure (2012) (0)
The Impact of American College of Cardiology Chest Pain Center Accreditation on Guideline Recommended Acute Myocardial Infarction Management (2021) (0)
Abstract 3301: Blood Transfusion and Mortality Among Patients with Non-ST-segment Elevation Acute Coronary Syndromes: Results from CRUSADE (2006) (0)
Abstract 15834: Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years (2013) (0)
Abstract 6084: Long-Term Prognostic Impact of ST-elevation vs. Non-ST-elevation Myocardial Infarction (2008) (0)
Women2011 Update: A Guideline From the American Heart Association Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in (2011) (0)
ROUTINE EARLY EPTIFIBATIDE, INFARCT SIZE, AND OUTCOMES IN NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME PATIENTS WITH ELEVATED TROPONIN ON ADMISSION (2012) (0)
Adverse Pregnancy Outcomes Are Associated With Coronary Artery and Cardiovascular Disease Risk (2006) (0)
Abstract 10358: Radial versus Femoral Approach in Non-ST Elevation ACS: Lessons From EARLY (2010) (0)
Degree of baseline risk should, but does not, influence treatment decisions in non-ST elevation acute coronary syndromes: Evidence from international clinical trials (2003) (0)
Implications of High-Sensitivity Troponin Testing Learning From Those Who Us* (2018) (0)
Letter to the editor [2] (multiple letters) (2004) (0)
PROGNOSTIC IMPLICATIONS OF LOW-LEVEL CARDIAC TROPONIN ELEVATION USING THE HIGH-SENSITIVITY ASSAY FOR CARDIAC TROPONIN T: RESULTS FROM EARLY ACS & SEPIA-TIMI 42 (2013) (0)
Randomized Clinical Trials Patient- and Trial-Speciﬁc Barriers to Participation in Cardiovascular Randomized Clinical Trials (2013) (0)
Review: Carvedilol may reduce mortality more than other β1-selective β-blockers in systolic HF (2013) (0)
TWO YEAR EXPERIENCE WITH HIGH-SENSITIVITY TROPONIN TESTING:INTERPRETATIVE VALUES FOR IMPROVING PATIENT DISPOSITION (2022) (0)
Chronic Kidney Disease and CoronaryArtery Disease (0)
CHAPTER 58 – Acute Coronary Syndromes (2009) (0)
Predictors of Stress-Delta High-Sensitivity Troponin T in Emergency Department Patients Undergoing Stress Testing (2022) (0)
AHA Scientific Statement Medication Errors in Acute Cardiovascular and Stroke Patients (2010) (0)
Heart Disease in Women (2018) (0)
Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C (2022) (0)
In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year (2020) (0)
Abstract 14779: A Simple, Highly-Sensitive Clinical Prediction Rule to Exclude Acute Coronary Syndrome in a Population with a High Burden of Cardiac Risk Factors (2014) (0)
Sex Differences in 1-Year Mortality Following Acute Coronary Syndromes (2008) (0)
Stress-Delta B-Type Natriuretic Peptide Does Not Exclude ACS in the ED. (2022) (0)
D IFFERENCES IN L EVEL OF C ARE AT THE E ND OF L IFE A CCORDING TO R ACE (2010) (0)
Abstract 13168: Sustained Ventricular Tachycardia and Ventricular Fibrillation are Infrequent Events but are Associated with Increased Arrhythmic and All-cause Death Following Non-ST-Segment Elevation Acute Coronary Syndromes (2010) (0)
Chronic Kidney Disease and Coronary Artery Disease (0)
Chapter 25 – Acute Coronary Syndromes (2010) (0)
Abstract 16557: Revascularization versus Optimal Medical Therapy for Patients With Prior Coronary Artery Bypass Surgery: An Analysis From the Duke Databank for Cardiovascular Disease (2015) (0)
Diabetes-related knowledge is not associated with measures of risk factor control in patients with diabetes and acute coronary syndromes (2002) (0)
Any Troponin Elevation Is Associated with Increased Mortality in Patients with Non-ST-Elevation Acute Coronary Syndromes Despite Variations in Hospital Laboratory Assays and Presence of Renal Insufficiency (2005) (0)
Abstract 6083: Sex Differences in 1-Year Mortality Following Acute Coronary Syndromes (2008) (0)
Moderna COVID-19 vaccine was linked to myocarditis or myopericarditis at 28 d (4.2 events/100 000 persons) (2022) (0)
Abstract 5764: Discharge Without Antiplatelet Therapy After Inhospital Bleeding is an Independent Predictor of 6-Month Mortality Among Patients With Acute Coronary Syndrome: A Pooled Analysis From PURSUIT, PARAGON-A, PARAGON-B and SYNERGY (2009) (0)
Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control (2017) (0)
Abstract 2002: Importance of Glomerular Filtration Rate Formula for Determining Chronic Kidney Disease and Clinical Care in Patients with Acute Coronary Syndromes (2006) (0)
ASSOCIATION BETWEEN ADMISSION HEMOGLOBIN LEVEL AND GUIDELINE-BASED THERAPY IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE NCDR® (2012) (0)
Outpatient Medications in Atrial Fibrillation (2016) (0)
American Heart Association Cardiac Arrest Survival Summit Arrest in the United States : Consensus Recommendations From the 2009 Implementation Strategies for Improving Survival After Out-of-Hospital Cardiac (2011) (0)
THE HIGH COST OF LOW ACUITY NON ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME ADMISSIONS TO THE CORONARY CARE UNIT: AN ANALYSIS OF NATIONAL POPULATION HEALTH DATA (2017) (0)
Review: Angiotensin-receptor blockers do not increase adverse cardiovascular outcomes (2011) (0)
SAFETY AND EFFICACY OF ADJUSTED-DOSE EPTIFIBATIDE IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND REDUCED RENAL FUNCTION (2010) (0)
Preoperative Evaluation for Major Noncardiac Surgery (2016) (0)
Erratum: Correction: Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings (Global heart (2020) 15 1 (44)) (2020) (0)
Review: In patients having PCI, high-dose clopidogrel reduces major cardiac events vs standard-dose clopidogrel (2015) (0)
Alternatives to Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation: A Look Back at the State of the Field in 2012 (2013) (0)
It Happened While You Were Sleeping (2016) (0)
DUAL ANTIPLATELET THERAPY PRIOR TO CABG (2016) (0)
Practice Guidelines : Clinical Utilization of Cardiac Biomarker Testing in Heart Failure WRITING GROUP MEMBERS (2007) (0)
Abstract 12777: More Bleeding but No Additional Efficacy with Increasing Age in High-risk ACS Patients Treated with Early vs. Delayed, Provisional Eptifibatide (2010) (0)
Association of Circulating Metabolites With Disease Severity and Mortality in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry (2023) (0)
Chest Pain: A Scientific Statement From the American Heart Association (2011) (0)
Past Successes of Genetic Findings Familial Hypercholesterolemia and Low-Density Lipoprotein Cholesterol Lowering (2015) (0)
Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials (2013) (0)
From the American Heart Association Medication Errors in Acute Cardiovascular and Stroke Patients: A Scientific Statement (2013) (0)
Abstract 17437: Do Patients With Uncomplicated Non-ST Segment Acute Coronary Syndromes Require Admission to Critical Care Units? (2015) (0)
Abstract 14618: Fasting Glucose, NT-proBNP, Treatment With Glycoprotein IIb/IIIa Inhibitors, and Outcomes in Non-ST-Segment Elevation Acute Coronary Syndromes: An Analysis From EARLY ACS (2013) (0)
Early Routine Eptifibatide Use is Not Superior to Delayed Provisional Use in NSTE ACS (2009) (0)
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events (2017) (0)
Correction: Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings (2020) (0)
Patients With Acute Coronary Syndromes Admitted to Contemporary Cardiac Intensive Care Units: Insights From the CCCTN Registry (2022) (0)
Review: Angiotensin-receptor blockers increase risk for cancer but not cancer-related death (2010) (0)
CVD Prevention and Treatment in Women with Diabetes (2012) (0)
TRENDS IN CARDIAC BIOMARKER PROTOCOLS AND TROPONIN CUT-POINTS (2016) (0)
Review: In HF with iron deficiency, iron supplementation reduces HF admissions and improves cardiac function (2019) (0)
Does Troponin Positivity Add Prognostic Value to Quantitative ST Segment Depression in Predicting Death and Myocardial Infarction in Non-ST Elevation Acute Coronary Syndrome Patients? (2002) (0)
Pooled RCTs: CABG reduces mortality more than PCI with DES in nondiabetic patients with multivessel CAD (2016) (0)
EFFECT OF EXERCISE ON PERIPHERAL GENE EXPRESSION IN CORONARY ARTERY DISEASE (2014) (0)
In HF with iron deficiency, IV ferric derisomaltose was associated with lower rates of HF hospitalization or CV death (2023) (0)
Novel Markers in Patients with Suspected Acute Coronary Syndromes (2009) (0)
CLOPIDOGREL IS NOT COMMONLY USED BUT ASSOCIATED WITH LESS RE-HOSPITALIZATION IN PATIENTS WITH PERIOPERATIVE MYOCARDIAL INFARCTION FOLLOWING CABG SURGERY (2017) (0)
Review: high dose statins reduce risk of non-fatal cardiovascular events more than standard dose statins. (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Laura Kristin Newby?

Laura Kristin Newby is affiliated with the following schools:

Laura Kristin Newby's Academic­Influence.com Rankings

Why Is Laura Kristin Newby Influential?

Laura Kristin Newby's Published Works

Published Works

What Schools Are Affiliated With Laura Kristin Newby?

Laura Kristin Newby's AcademicInfluence.com Rankings